<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[ranbaxy Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/ranbaxy.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to ranbaxy]]></description>
	<s:counts start="0" returned="20" found="31" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Ranbaxy suffers 53% fall in US sales]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fwww.ft.com%2Fcms%2Fs%2F0%2F7d58ab82-c263-11de-be3a-00144feab49a.html&siteid=23&tag=financialtimes]]></link>
		<description><![CDATA[ The financial pain inflicted by a US import ban on some of the products of Ranbaxy Laboratories, India's largest drugsmaker, continues to hurt the company a year after it was first imposed.In the US, sales fell 53 per cent to $44m during the quarter to the end of September...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 26 Oct 2009 13:34:42 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/ranbaxy+laboratories+ltd..html"><![CDATA[Ranbaxy Laboratories Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[Ranbaxy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/company+news.html"><![CDATA[Company News]]></category>
		<category domain="http://resources.bnet.com/topic/economic+news.html"><![CDATA[Economic News]]></category>
		<category domain="http://resources.bnet.com/topic/foreign+trade.html"><![CDATA[Foreign Trade]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/regulation+of+business.html"><![CDATA[Regulation of Business]]></category>
		<category domain="http://resources.bnet.com/topic/financial+times.html"><![CDATA[Financial Times]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">RBXZ F</category>
		<category domain="tickers">RBXZ F</category>
	</item>
	<item>
		<title><![CDATA[Ranbaxy Rejects Allegations]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_qa5292/is_20080721/ai_n28055008]]></link>
		<description><![CDATA[Indian generic drug maker Ran- baxy Laboratories Ltd., which has its U.S. offices in Plainsboro, said last week it has agreed to produce specific documents sought by the U.S. Department of Justice in an investigation into alleged falsification of data relating to generic drugs. On July 3, the Justice Department...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 21 Jul 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[Ranbaxy]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+department+of+justice.html"><![CDATA[U.S. Department of Justice]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Pfizer Cuts a Deal -- No Bid for Ranbaxy]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000103/pfizer-cuts-a-deal-no-bid-for-ranbaxy/]]></link>
		<description><![CDATA[So Pfizer apparently won't be playing the spoiler in the Daiichi-Ranbaxy merger after all. Instead, CEO Jeff Kindler cut a deal with the Indian generics maker that will delay the introduction of generic Lipitor by about 20 months.    Ranbaxy is now spared the cost and uncertainty involved...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 18 Jun 2008 11:35:08 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[Patent]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[Agreement]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[Ranbaxy]]></category>
		<category domain="http://resources.bnet.com/topic/lipitor.html"><![CDATA[Lipitor]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[On the Birla Bandwagon ; Why Ajay Srinivasan quit the global stage and headed home.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5644/is_200712/ai_n23672691]]></link>
		<description><![CDATA[On the Birla Bandwagon Why Ajay Srinivasan quit the global stage and headed home. By Anand AdhikariFew can boast a career graph that's been as meteoric and at the same time as unpredictable as that of Ajay Srinivasan. Close to a decade ago he took charge of Prudential Plc's Indian...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Sun, 30 Dec 2007 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/abb.html"><![CDATA[ABB]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/financial.html"><![CDATA[financial]]></category>
		<category domain="http://resources.bnet.com/topic/india.html"><![CDATA[India]]></category>
		<category domain="http://resources.bnet.com/topic/mindtree+consulting.html"><![CDATA[MindTree Consulting]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[Ranbaxy]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[SALES]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABB</category>
		<category domain="tickers">ABB</category>
	</item>
	<item>
		<title><![CDATA[Ranbaxy loses battle for Lipitor patent in Canada.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5936/is_200709/ai_n23954766]]></link>
		<description><![CDATA[Sep. 14--NEW DELHI -- In a setback for Ranbaxy in its global battle  over the patent of Lipitor, a Canadian federal court has ruled that the  company's generic drug Atorvastatin infringes upon one of  Pfizer's Lipitor patent. However, the court dismisse  Sep. 14--NEW DELHI -- In...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 14 Sep 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/lipitor.html"><![CDATA[Lipitor]]></category>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[patent]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[Ranbaxy]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Pharma patent disputes out-of-court.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5936/is_200708/ai_n23954483]]></link>
		<description><![CDATA[Byline: Noemie Bisserbe    Aug. 2--MUMBAI, India -- As litigation costs soar, several generic  drug makers and innovative pharma companies are settling patent disputes  out of court. In these settlements, the generic company usually agrees  to delay its entrance in the market, in exchange for...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 02 Aug 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[agreement]]></category>
		<category domain="http://resources.bnet.com/topic/ftc.html"><![CDATA[FTC]]></category>
		<category domain="http://resources.bnet.com/topic/litigation.html"><![CDATA[Litigation]]></category>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[patent]]></category>
		<category domain="http://resources.bnet.com/topic/payment.html"><![CDATA[payment]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[Ranbaxy]]></category>
		<category domain="http://resources.bnet.com/topic/settlement.html"><![CDATA[settlement]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[High Court in Dublin Rules in Pfizer's Favor in Patent Case, Lipitor Protected from Generic Competition until 2011]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_July_10/ai_n27298513]]></link>
		<description><![CDATA[NEW YORK -- Pfizer Inc said today that the High Court in Dublin, Ireland has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be infringed by a competitor product from generics manufacturer Ranbaxy. The decision, which is subject to a possible appeal, prevents...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 10 Jul 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/lipitor.html"><![CDATA[Lipitor]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[Ranbaxy]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Ranbaxy-GSK to develop respiratory drug.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5936/is_200704/ai_n23953323]]></link>
		<description><![CDATA[Apr. 4--NEW DELHI -- Ranbaxy will develop a respiratory  inflammation drug in collaboration GlaxoSmithKline GSK, as part of  their new multi-year R&D agreement, a Ranbaxy release on Monday  said. Ranbaxy could get up to $100 million in potential milestone  payments for a product developed by it...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 04 Apr 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[agreement]]></category>
		<category domain="http://resources.bnet.com/topic/collaboration.html"><![CDATA[Collaboration]]></category>
		<category domain="http://resources.bnet.com/topic/economic+times.html"><![CDATA[Economic Times]]></category>
		<category domain="http://resources.bnet.com/topic/groupware.html"><![CDATA[Groupware]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/inflammation.html"><![CDATA[inflammation]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[Ranbaxy]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[SOFTWARE]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[PPD deal worth $44 m for Ranbaxy.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5936/is_200703/ai_n23952959]]></link>
		<description><![CDATA[Mar. 10--BANGALORE, India -- The recent in-licensing deal between  Indian pharma major Ranbaxy and PPD, a Nasdaq-listed contract research  organisation CRO, could be worth up to $44 million for the  Gurgaon-based company, the Wilmington, North Carolina-based CRO has  said.    In its form 8-K...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Sat, 10 Mar 2007 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/economic+times.html"><![CDATA[Economic Times]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[Ranbaxy]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[SALES]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Ranbaxy gets US nod to mkt its drug.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5936/is_200702/ai_n23952403]]></link>
		<description><![CDATA[Feb. 1--NEW DELHI -- Gurgaon-based pharmaceutical major Ranbaxy  Labs today announced that RLL has received approval from the US Food and  Drug Administration to market Amoxicillin and Clavulanate Potassium for  Oral Suspension. The Division of Bioequivalence has determined the  Ranbaxy formulation to be bioequivalent and, therefore,...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 01 Feb 2007 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/economic+times.html"><![CDATA[Economic Times]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[formulation]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[Ranbaxy]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy+laboratories+ltd..html"><![CDATA[Ranbaxy Laboratories Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[SALES]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">RBXZ F</category>
		<category domain="tickers">GSK,RBXZ F</category>
	</item>
	<item>
		<title><![CDATA[Going, Going... Gone Global In the next 15 years, India Inc. will be a name to reckon with all over the world-and many more foreign transnational giants would have bought their way into a still piping-hot domestic market.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5644/is_200701/ai_n23672252]]></link>
		<description><![CDATA[At the beginning of 2006, if any pundit was to venture that Tata Steel would be willing to fork out $10 billion for Europe's second- largest steel maker, or that Ranbaxy would have concluded eight overseas acquisitions in the year, his predictions would hAt the beginning of 2006, if any...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Sun, 14 Jan 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[RANBAXY]]></category>
		<category domain="http://resources.bnet.com/topic/tata+steel+ltd..html"><![CDATA[Tata Steel Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[PFIZER INC - Statement re: Pfizer Lipitor patent in Australia.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5937/is_200612/ai_n23962586]]></link>
		<description><![CDATA[Australian Federal Court Upholds Basic Lipitor Patent, Preventing Launch of                              Generic Ranbaxy Product        ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 20 Dec 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[patent]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[RANBAXY]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[PFIZER INC - Pfizer Lipitor patent case.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5937/is_200610/ai_n23961992]]></link>
		<description><![CDATA[U.S. Appeals Court Denies Ranbaxy Petition for Rehearing Regarding Main Patent                                 in Lipitor Case    ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 24 Oct 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/lipitor.html"><![CDATA[Lipitor]]></category>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[patent]]></category>
		<category domain="http://resources.bnet.com/topic/petition.html"><![CDATA[petition]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[Ranbaxy]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[PFIZER INC - Lipitor Norway Decision.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5937/is_200608/ai_n23961503]]></link>
		<description><![CDATA[Norway Court Decision 'Has No Practical Effect on Pfizer's Ability to Protect       Lipitor from the Launch of a Competitor Generic Product By Ranbaxy'        NEW YORK, Aug. 30 -- Pfizer Inc said today that a Norwegian court ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 30 Aug 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/lipitor.html"><![CDATA[Lipitor]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[RANBAXY]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Ranbaxy gets taste of Merck bestseller.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5936/is_200605/ai_n23948471]]></link>
		<description><![CDATA[May 3--NEW DELHI -- Ranbaxy and Israeli generic major Teva  Pharmaceutical are likely to get a windfall by having six months without  competition to sell their generic versions of Merck's blockbuster  cholesterol drug Zocor.    May 3--NEW DELHI -- Ranbaxy and Israeli generic major Teva...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 03 May 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[Ranbaxy]]></category>
		<category domain="http://resources.bnet.com/topic/zocor.html"><![CDATA[ZOCOR]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[US generics lures pharma cos again.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5936/is_200602/ai_n23946669]]></link>
		<description><![CDATA[Feb. 15--NEW DELHI -- Some good news may finally be round the  corner for domestic pharma majors Ranbaxy and Dr Reddy's  Laboratories, among others.    They were hit hard by price erosion in the US generic market last  year, but analysts now project an upward...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 15 Feb 2006 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merrill+lynch+%2526+co.+inc..html"><![CDATA[Merrill Lynch & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[patent]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[Ranbaxy]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MER</category>
		<category domain="tickers">MER</category>
	</item>
	<item>
		<title><![CDATA[Dr Reddy's, Ranbaxy lead race for German co.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5936/is_200602/ai_n23946406]]></link>
		<description><![CDATA[Feb. 8--Only Ranbaxy and Dr Reddy's seem to be left in the  race for the German generic company Betapharm Arzneimittel. According to  banking sources, the two companies are in the lead and one of them is  likely to clinch the deal.    The industry buzz...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 08 Feb 2006 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/banking.html"><![CDATA[Banking]]></category>
		<category domain="http://resources.bnet.com/topic/economic+times.html"><![CDATA[Economic Times]]></category>
		<category domain="http://resources.bnet.com/topic/europe.html"><![CDATA[Europe]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/germany.html"><![CDATA[Germany]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[Ranbaxy]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
	</item>
	<item>
		<title><![CDATA[Ranbaxy mixes bitter pill for Eli Lilly.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5936/is_200601/ai_n23946093]]></link>
		<description><![CDATA[Jan. 28--NEW DELHI -- In one of the high-profile patent disputes,  multinational drug maker Eli Lilly's patent application for  erectile dysfunction drug Cialis has been opposed by Ranbaxy at the  pre-grant opposition stage.    Jan. 28--NEW DELHI -- In one of the high-profile patent disputes,...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Sat, 28 Jan 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[RANBAXY]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
	<item>
		<title><![CDATA[Ranbaxy in pact with Swiss company.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5936/is_200601/ai_n23945626]]></link>
		<description><![CDATA[Jan. 11--DELHI -- Ranbaxy on Tuesday announced a co-marketing  agreement with Ferring International of Switzerland, a speciality  biopharmaceutical company, for the latter's hormone tablet  Desmopressin in India. Desmopressin, a structural analogue of the  pituitary hormone Arginine Vasopressin, is used to treat Nocturia, a  condition seen...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 11 Jan 2006 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[agreement]]></category>
		<category domain="http://resources.bnet.com/topic/economic+times.html"><![CDATA[Economic Times]]></category>
		<category domain="http://resources.bnet.com/topic/hardware.html"><![CDATA[HARDWARE]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[Ranbaxy]]></category>
		<category domain="http://resources.bnet.com/topic/tablets.html"><![CDATA[Tablets]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Passion to Win: How Winning Companies Develop and Sustain Competitive Edge]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_qa5483/is_200601/ai_n21406597]]></link>
		<description><![CDATA[Passion to Win: How Winning Companies Develop and Sustain Competitive Edge By Abad Ahmad and O P Chopra Excel Books Private Limited, New Delhi, 2004; Pages: 322; Price: Rs. 250; ISBN: 81-7446-389-5. This book is the product of the efforts of two Delhi University Professors, Abad Ahmad and O P...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Sun, 01 Jan 2006 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/honda+motor+co..html"><![CDATA[Honda Motor Co.]]></category>
		<category domain="http://resources.bnet.com/topic/productivity.html"><![CDATA[PRODUCTIVITY]]></category>
		<category domain="http://resources.bnet.com/topic/ranbaxy.html"><![CDATA[Ranbaxy]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[SALES]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/telecommunications.html"><![CDATA[TELECOMMUNICATIONS]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">HMC</category>
		<category domain="tickers">HMC</category>
	</item>
</channel>
</rss>
